Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26979390.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0372.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The proliferative component of chronic myelomonocytic leukemia, related to an increased sensitivity of myeloid progenitors to granulocyte macrophage-colony stimulating factor, suggests dedicated therapeutic approaches. In this issue, ruxolitinib, a JAK1 and -2 inhibitory drug, is shown to induce objective responses in chronic myelomonocytic leukemia patients. Clin Cancer Res; 22(15); 3707-9. ©2016 AACRSee related article by Padron et al., p. 3746.
Medical subject headings
- Antinematodal Agents
- Granulocyte-Macrophage Colony-Stimulating Factor
- Janus Kinases
- Leukemia, Myelomonocytic, Chronic
- Pyrazoles
- STAT Transcription Factors